Hongguk Kim and related parties' stake slightly up to 50.46%... No dilution risk despite extension of share pledge agreements, management control stable
The stake of major shareholder Hongguk Kim and related parties increased by 0.20%p from 50.26% to 50.46% (226,300 shares purchased on market)
The increase was from open market purchases by related party Korea Biotech Co., Ltd. (average price ~12,000 KRW), funded by its own funds and a KRW 2 billion loan from Korea Securities Finance
Share pledge agreements were amended: Olpoom's KRW 16 billion loan from KDB extended, and Korea Biotech's new KRW 2 billion loan from Korea Securities Finance, with no change in pledged shares
Total pledged shares remain at 10,205,752 (9.11%) vs prior report, no additional pledges
Stated no specific plans other than maintaining management influence, current control is stable
[AI Comprehensive Analysis]This disclosure is a routine update with a minor stake increase and pledge extension, having no material impact on enterprise value. The likelihood of future control change or additional financing is low, making it a neutral event for shareholders.